Drug intelligence / Profile preview

ZVS106e

Development stage: Phase 1
Lead developer: Chigenovo
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Ophthalmic

Overview

ZVS106e is an investigational, subretinally administered **recombinant adeno-associated virus serotype 8 gene-replacement therapy** for inherited retinal degeneration caused by biallelic **ABCA4** mutations, including Stargardt disease type 1. The injection contains two active rAAV8 vector components, ZVS106E-A and ZVS106E-B, intended to restore functional ABCA4 activity in affected retinal cells. It is being evaluated in an early-phase clinical study using a single unilateral subretinal injection. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT07241169/))

Other names: ZVC 106eZVC106eZVC-106eZVS-106eZVS106eZVS 106e

Targets

ABCA4

Beyond the preview

Go deeper on ZVS106e.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZVS106e.

Explore the full profile